opinion web
Liberal Opinion General Opinion
Betsy McCaughey
Liberty Belle
21 Jan 2015
Cadillac Tax: Clunker for Labor, Opportunity for GOP

There's one part of Obamacare that even Democrats hate: the Cadillac tax. It doesn't go into effect until 2018,… Read More.

14 Jan 2015
CDC No Longer Keeps Us Safe

With flu raging through 46 states, the Centers for Disease Control and Prevention is taking center stage, … Read More.

7 Jan 2015
"The Nurse Will See You Now"

Next time you're a patient, ask whether your "health care provider" is a doctor. On January 1, New York State … Read More.

Obamacare Vs. Cancer Cures


Even Republicans gushed with enthusiasm when President Barack Obama announced funding for personalized medicine during the State of the Union last week. "I am launching a new precision medicine initiative," Obama said, to usher in a "new era of medicine, one that delivers the right treatment at the right time."

Sounds good, but don't be fooled. The biggest impediment to these cures is Obamacare, and the loudest critic of personalized medicine is Obamacare architect Dr. Ezekiel Emanuel.

Scientists already have turned the corner from one-size-fits-all medicine to fashioning cures based on a patient's genetic makeup. Not all breast cancers or lung cancers or other afflictions are alike. They differ depending on a patient's genes. Testing patients to see what genetic mutation is causing their sickness and then using a drug that targets it avoids wasting time on drugs that won't work or would even make a patient sicker.

It should be the future of medicine, but Obamacare stands in the way. Members of Congress would know that if they had bothered to read the law. Obamacare forces doctors to practice one-size-fits-all medicine. The law whacks them with financial penalties if they stray from what Washington calls "evidence-based" treatments.

"Evidenced-based" means the treatment that works best for the majority of patients. Too bad if you're not the typical patient. As Dr. Jeffrey Singer, a surgeon and adjunct fellow at the Cato Institute, says, "It is easy to standardize treatment protocols. But it is difficult to standardize patients."

Then there's the delay between discovering a new treatment and when it becomes standard practice. That takes 17 years, complains Dr. Eric Topol, a cardiologist and geneticist formerly at the Cleveland Clinic. Too long for a patient with cancer or heart disease.

In a debate with Topol at The Aspen Institute, Emanuel objected that tailor-making treatments is extravagant, like wearing a custom-made suit rather than one off the rack. Emanuel advocates standardizing how doctors treat patients. He says, "We need to be skeptical ... that personalized medicine is going to produce cost savings and be so much better for the system."

Better for the system? Maybe that's what Emanuel thinks is important.

But the goal should be what's better for the patient, and there's no question that personalized medicine is better.

Yet Obamacare makes it almost impossible to get.

First, Obamacare health plans limit access to cancer hospitals and specialists. The Associated Press showed in 2014 that most Obamacare enrollees weren't covered to use Memorial Sloan Kettering in New York City or MD Anderson in Houston, for example. In 2015, access is just as limited, reports Kaiser Health News.

Second, these Obamacare plans jack up co-pays for targeted therapies the president is praising. A new HealthPocket report shows that patients in silver plans will be socked with a $5,569 co-pay for the cancer drug Gleevec (for chronic myeloid leukemia). That's after already spending $5,000 or more to meet the plan's deductible.

Third, seniors are also losing access to personalized medicine because of Obamacare's Medicare Shared Savings Program. The Obama administration announced on January 26 that Medicare will gradually stop paying doctors for the care they provide to an individual patient, and will instead pay a fixed fee to take care of a large group. Doctors and hospitals that spend less than the fixed fee get to keep a portion of the "savings." This will encourage them to skimp on care. It's the old HMO model rewrapped

In 2010, the Affordable Care Act launched this idea as a pilot program. It didn't work, yet Health and Human Services Secretary Sylvia Burwell announced on Monday that it will be expanded to cover at least 50 percent of Medicare patients by 2018. Good luck to patients who need expensive targeted gene therapies. Whatever is prescribed for the patient comes out of doctors' own pockets at the end of the year. It sets up a conflict between you and the doctor you should be able to trust.

So hold the applause for the president's seemingly magnanimous offer to fund research on personalized medicine. Research is good, but scientists and investors are already bringing these breakthroughs to market. What's standing between you and these lifesaving treatments is Obamacare.

Betsy McCaughey, Ph.D., is chairman of the Committee to Reduce Infection Deaths and a senior fellow at the London Center for Policy Research. To find out more about Betsy McCaughey and read features by other Creators Syndicate writers and cartoonists, visit the Creators Syndicate website at



0 Comments | Post Comment
Already have an account? Log in.
New Account  
Your Name:
Your E-mail:
Your Password:
Confirm Your Password:

Please allow a few minutes for your comment to be posted.

Enter the numbers to the right: comments policy
Betsy McCaughey
Jan. `15
Su Mo Tu We Th Fr Sa
28 29 30 31 1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31
About the author About the author
Write the author Write the author
Printer friendly format Printer friendly format
Email to friend Email to friend
View by Month
Deb Saunders
Debra J. SaundersUpdated 1 Feb 2015
Lawrence Kudlow
Lawrence KudlowUpdated 31 Jan 2015
Brent Bozell

14 May 2014 More Than Talk Needed to Rescue Trapped Vets

30 Oct 2013 A Lie from Day One

5 Nov 2014 The Ebolacare Factor in the Election